1. Acetylcholine (ACh) is synthesized in the cytoplasm of cholinergic nerve terminals. Which of the following correctly identifies the enzyme responsible, the substrates required, and the clinical significance of this synthesis step?

• A) Acetylcholine is synthesized from acetyl-CoA (derived from glucose metabolism in the mitochondria) and choline (transported into the nerve terminal from the synaptic cleft by the high-affinity choline transporter, CHT1) by the enzyme choline acetyltransferase (ChAT) — ChAT is expressed exclusively in cholinergic neurons and its presence is used as a histological marker to identify cholinergic cell bodies; the rate-limiting step in ACh synthesis is choline availability, which is why the high-affinity choline transporter is a pharmacological target for research into cholinergic enhancement
• B) Acetylcholine is synthesized from acetyl-CoA and serine by the enzyme choline acetyltransferase (ChAT) in the synaptic vesicle lumen — the vesicular location of synthesis ensures that newly synthesized ACh is immediately packaged for release without entering the cytoplasm; inhibition of ChAT by hemicholinium-3 is the basis of its use as a research tool to deplete cholinergic neurons
• C) Acetylcholine is synthesized from acetate and choline by acetylcholinesterase (AChE) running in reverse at high acetate concentrations — this reverse AChE reaction is the primary route of ACh synthesis in postganglionic parasympathetic neurons; the same enzyme that synthesizes ACh also terminates its action, making cholinergic neurotransmission uniquely self-regulating
• D) Acetylcholine is synthesized from choline and acetyl-CoA in the synaptic vesicle by vesicular acetylcholine transferase (VAChT) — VAChT serves a dual role as both the synthetic enzyme and the vesicular transporter, packaging ACh into vesicles as it is synthesized; inhibition of VAChT by vesamicol depletes ACh stores by simultaneously blocking synthesis and vesicular storage
• E) Acetylcholine is synthesized from phosphatidylcholine hydrolysis by phospholipase D in the presynaptic membrane — the choline released by membrane phospholipid breakdown provides the substrate for ACh synthesis, linking membrane lipid metabolism directly to neurotransmitter production; this pathway is upregulated during high-frequency cholinergic firing to maintain ACh availability

2. After synthesis, acetylcholine must be packaged into synaptic vesicles before it can be released. Which of the following correctly describes the vesicular packaging step and identifies the drug that exploits this step?

• A) Acetylcholine is packaged into synaptic vesicles by the vesicular acetylcholine transporter (VAChT), which uses the proton electrochemical gradient across the vesicle membrane (maintained by a vacuolar H+-ATPase) to drive ACh import in exchange for protons — vesamicol blocks VAChT, preventing vesicular ACh packaging and depleting the readily releasable pool of ACh without affecting cytoplasmic ACh synthesis; this mechanism is exploited experimentally to study cholinergic transmission
• B) Acetylcholine is packaged into synaptic vesicles by passive diffusion driven by the high concentration of ACh in the cytoplasm relative to the vesicle lumen — no specific transporter is required because ACh is a small positively charged molecule that crosses the lipid vesicle membrane by electrostatic attraction to the negatively charged interior of the vesicle
• C) Acetylcholine is packaged into vesicles by the same choline acetyltransferase (ChAT) enzyme that synthesizes it — after synthesis, ChAT undergoes a conformational change that converts it from a synthetic enzyme to a vesicular transporter, coupling synthesis and packaging in a single molecular step that prevents cytoplasmic ACh accumulation
• D) Acetylcholine packaging into vesicles is driven by the sodium-potassium ATPase in the vesicle membrane — Na+/K+-ATPase maintains a sodium gradient across the vesicle membrane that drives secondary active transport of ACh into the vesicle lumen in exchange for sodium ions moving down their concentration gradient
• E) Acetylcholine does not require vesicular packaging before release — it is released directly from the cytoplasm through plasma membrane ACh channels that open during action potential arrival; vesicles in cholinergic terminals contain neuropeptide co-transmitters only, and ACh release is therefore non-quantal and continuous rather than phasic and stimulus-dependent

3. Norepinephrine (NE) synthesis in sympathetic postganglionic neurons proceeds through a series of enzymatic steps beginning with the amino acid tyrosine. Which of the following correctly identifies the rate-limiting enzyme in this pathway and the cofactor it requires?

• A) The rate-limiting enzyme is dopamine beta-hydroxylase (DBH), which converts dopamine to norepinephrine inside the synaptic vesicle — DBH requires ascorbic acid (vitamin C) as a cofactor; this is why severe vitamin C deficiency (scurvy) produces autonomic symptoms including orthostatic hypotension from impaired norepinephrine synthesis
• B) The rate-limiting enzyme is aromatic L-amino acid decarboxylase (AAAD, also called DOPA decarboxylase), which converts L-DOPA to dopamine — AAAD requires pyridoxal phosphate (vitamin B6) as a cofactor and is expressed not only in catecholaminergic neurons but also in peripheral tissues; inhibiting AAAD peripherally (with carbidopa) is used clinically to prevent peripheral L-DOPA metabolism in Parkinson disease treatment
• C) The rate-limiting enzyme is tyrosine hydroxylase (TH), which converts tyrosine to L-DOPA — TH requires tetrahydrobiopterin (BH4) as a cofactor and molecular oxygen; TH activity is regulated by end-product inhibition (NE and dopamine compete with BH4 for binding to TH), by phosphorylation (increased firing increases TH phosphorylation and activity), and by gene transcription changes during chronic stimulation; inhibition of TH by alpha-methyl-para-tyrosine (metyrosine) depletes catecholamine stores and is used clinically in pheochromocytoma management
• D) The rate-limiting enzyme is phenylethanolamine N-methyltransferase (PNMT), which converts norepinephrine to epinephrine — PNMT requires S-adenosylmethionine (SAM) as a methyl donor and is expressed almost exclusively in the adrenal medulla; PNMT inhibition with SK&F 29661 depletes epinephrine selectively without affecting norepinephrine levels, making it a useful research tool for dissecting adrenomedullary from sympathoneuronal catecholamine contributions
• E) The rate-limiting enzyme is monoamine oxidase (MAO), which converts dopamine to norepinephrine by oxidative deamination followed by beta-hydroxylation — MAO requires FAD as a cofactor; this dual role of MAO in both NE synthesis and degradation explains why MAO inhibitors paradoxically increase NE synthesis while simultaneously preventing NE breakdown

4. Norepinephrine release from sympathetic nerve terminals occurs by calcium-dependent exocytosis. Which of the following correctly describes the sequence of events from action potential arrival to NE release, and identifies what triggers the calcium influx?

• A) Action potential depolarization opens voltage-gated calcium channels (primarily N-type and P/Q-type) in the presynaptic terminal membrane — calcium influx activates SNARE protein-mediated vesicle docking and fusion with the plasma membrane, releasing NE into the synaptic cleft by exocytosis; the quantal nature of NE release reflects the all-or-none fusion of individual vesicles containing fixed amounts of NE; botulinum toxin cleaves SNARE proteins, preventing vesicle fusion and blocking NE release
• B) Action potential depolarization directly opens ligand-gated calcium channels at the presynaptic terminal — these channels are activated by the binding of NE itself in a positive feedback loop that amplifies NE release; the alpha-2 presynaptic autoreceptor is the ligand-gated calcium channel responsible for calcium influx and NE exocytosis
• C) Action potential depolarization activates the sodium-calcium exchanger (NCX) in the presynaptic terminal membrane, which runs in reverse during depolarization to import calcium in exchange for sodium export — this reverse NCX mode is the primary calcium entry mechanism for NE release; NCX inhibitors therefore block sympathetic neurotransmission by preventing calcium-triggered exocytosis
• D) Action potential depolarization triggers calcium release from the presynaptic endoplasmic reticulum through IP3 receptors — the rise in intracellular calcium from internal stores is sufficient to trigger NE exocytosis without any calcium entry from the extracellular space; this internal calcium release mechanism explains why sympathetic neurotransmission persists in low extracellular calcium conditions
• E) Action potential depolarization opens voltage-gated sodium channels in the vesicle membrane — sodium influx into the vesicle lumen alkalinizes the vesicle interior and destabilizes the NE-chromogranin complex, causing osmotic swelling and passive NE efflux through stretch-activated pores in the vesicle membrane without requiring membrane fusion

5. After release into the synaptic cleft, the action of norepinephrine is terminated primarily by reuptake into the presynaptic terminal. Which of the following correctly identifies the transporter responsible and explains the pharmacological significance of this reuptake mechanism?

• A) Norepinephrine diffuses from the synaptic cleft into the systemic circulation where it is degraded by hepatic COMT and MAO — diffusion is the primary termination mechanism for NE released at sympathetic neuroeffector junctions; reuptake transporters serve only to recycle NE metabolites back into the nerve terminal for vesicular repackaging rather than for intact NE inactivation
• B) Norepinephrine is degraded exclusively in the synaptic cleft by catechol-O-methyltransferase (COMT), which methylates the catechol ring using S-adenosylmethionine as a methyl donor — COMT is the primary termination mechanism for NE action; reuptake plays no significant role in NE inactivation at sympathetic nerve terminals, and NET is expressed only in the CNS where it handles dopamine rather than NE reuptake
• C) Norepinephrine is taken up from the synaptic cleft by the extraneuronal monoamine transporter (EMT, also called Uptake 2 or OCT3) located on postsynaptic effector cells and non-neuronal tissues — EMT is the primary NE inactivation mechanism accounting for more than 90% of NE removal; NET (Uptake 1) plays only a minor role; corticosteroids block EMT, explaining part of their sympathomimetic effect
• D) Norepinephrine is taken up from the synaptic cleft by the norepinephrine transporter (NET, also called Uptake 1), a sodium- and chloride-dependent secondary active transporter located on the presynaptic sympathetic terminal — NET reuptake is the primary mechanism of NE inactivation, accounting for approximately 70–80% of released NE removal; drugs that block NET (tricyclic antidepressants, SNRIs, cocaine) prolong and intensify NE effects at adrenergic receptors; indirect sympathomimetics such as ephedrine and tyramine enter the terminal via NET and displace vesicular NE, producing NE release
• E) Norepinephrine action is terminated primarily by monoamine oxidase (MAO) located on the outer mitochondrial membrane within the sympathetic nerve terminal — MAO deaminates NE to 3,4-dihydroxyphenylglycol (DHPG) within milliseconds of release; NET reuptake serves to deliver NE to intraterminal MAO for degradation rather than functioning as an independent inactivation mechanism

6. Acetylcholinesterase (AChE) is the enzyme responsible for terminating acetylcholine action in the synaptic cleft. Which of the following correctly describes where AChE is located, how quickly it acts, and what happens when it is inhibited?

• A) AChE is located exclusively inside cholinergic nerve terminals, where it degrades any ACh that leaks from synaptic vesicles before release — AChE inhibition therefore increases intravesicular ACh concentration, producing larger quantal releases without affecting the duration of ACh action in the synaptic cleft, because extracellular AChE does not exist
• B) AChE is located in the synaptic cleft and on the postsynaptic membrane — it hydrolyzes ACh to choline and acetate within milliseconds of release, rapidly terminating cholinergic transmission; AChE inhibition (by drugs such as neostigmine, pyridostigmine, physostigmine, or organophosphate compounds) prevents ACh hydrolysis, allowing ACh to accumulate in the cleft and produce prolonged, intensified activation of both muscarinic and nicotinic receptors at all cholinergic synapses simultaneously
• C) AChE is located on the presynaptic terminal membrane where it acts as both a degradative enzyme and a vesicular transporter — after hydrolyzing ACh, the choline-AChE complex is internalized by endocytosis, delivering choline directly to ChAT for resynthesis; AChE inhibition therefore reduces ACh synthesis as well as prolonging its action, explaining why AChE inhibitors have a ceiling effect on their cholinomimetic activity
• D) AChE is a plasma enzyme synthesized by the liver that circulates in the bloodstream and diffuses into synaptic clefts — its plasma concentration determines the rate of ACh degradation at all cholinergic synapses; patients with liver failure develop cholinergic toxicity from reduced plasma AChE, which is why measuring plasma cholinesterase activity is used to assess the severity of organophosphate poisoning
• E) AChE acts slowly over minutes rather than milliseconds — cholinergic transmission is terminated primarily by ACh diffusion out of the synaptic cleft rather than by enzymatic hydrolysis; AChE serves mainly to prevent ACh from reaching the circulation and activating systemic muscarinic receptors, rather than to terminate local synaptic ACh action

7. Indirect sympathomimetics such as ephedrine and tyramine produce their effects by releasing norepinephrine from sympathetic nerve terminals rather than by directly activating adrenergic receptors. Which of the following correctly describes the mechanism by which they accomplish this?

• A) Indirect sympathomimetics bind to alpha-1 adrenergic receptors on the presynaptic terminal membrane and activate Gq/11 signaling, which triggers IP3-mediated calcium release from the terminal endoplasmic reticulum — this calcium surge produces calcium-dependent exocytosis of NE from vesicles, identical in mechanism to action potential-triggered release, explaining why indirect sympathomimetics produce the same pattern of receptor activation as direct-acting NE
• B) Indirect sympathomimetics enter the nerve terminal via the norepinephrine transporter (NET), either by carrier-mediated transport or by diffusion across the lipid membrane — once inside the terminal, they enter synaptic vesicles via VMAT2 and displace stored NE, driving NE efflux through the vesicle membrane into the cytoplasm; the high cytoplasmic NE concentration then drives reverse transport through NET, releasing NE into the synaptic cleft by non-exocytotic carrier-mediated efflux; because this mechanism bypasses calcium-dependent exocytosis, indirect sympathomimetics continue to release NE even when voltage-gated calcium channels are blocked
• C) Indirect sympathomimetics inhibit monoamine oxidase (MAO) within the sympathetic nerve terminal, preventing intraneuronal NE degradation and causing NE to accumulate in the cytoplasm to concentrations sufficient to drive diffusion across the presynaptic membrane into the synaptic cleft — this MAO inhibition mechanism is why indirect sympathomimetics produce tachyphylaxis: MAO recovers rapidly after drug washout, restoring normal NE degradation
• D) Indirect sympathomimetics block the norepinephrine transporter (NET) on the presynaptic terminal, preventing NE reuptake from the synaptic cleft — the accumulation of NE in the cleft from ongoing release constitutes the indirect sympathomimetic effect; this mechanism is identical to cocaine's sympathomimetic action, which is why cocaine and ephedrine are classified together as indirect sympathomimetics
• E) Indirect sympathomimetics directly open VMAT2 (the vesicular monoamine transporter) by binding to an allosteric site on its cytoplasmic domain — VMAT2 opening allows NE to flow passively down its concentration gradient from the vesicle lumen into the cytoplasm; the high cytoplasmic NE then activates presynaptic alpha-2 autoreceptors, paradoxically reducing further NE release through a negative feedback mechanism that limits the sympathomimetic effect

8. Reserpine depletes catecholamine stores by blocking the vesicular monoamine transporter (VMAT2, the transporter that packages dopamine and norepinephrine into storage vesicles). Which of the following correctly predicts the consequence of VMAT2 blockade in sympathetic nerve terminals and explains why reserpine produces a prolonged effect?

• A) VMAT2 blockade prevents dopamine and NE from entering synaptic vesicles — newly synthesized dopamine and NE accumulate in the cytoplasm where they are rapidly degraded by intraneuronal MAO; simultaneously, the unprotected vesicular NE leaks out of vesicles (which normally maintain a proton gradient that drives NE import) and is also degraded by MAO; the combined depletion of vesicular NE stores is prolonged because recovery requires both VMAT2 washout and resynthesis of NE over days to weeks, during which sympathetic neurotransmission is severely impaired; reserpine was historically used as an antihypertensive but was largely abandoned due to its side effect of depression from CNS monoamine depletion
• B) VMAT2 blockade causes immediate release of all vesicular NE into the synaptic cleft by osmotic pressure — when the vesicular proton gradient is disrupted, NE is released in a massive unregulated surge before stores are depleted; this initial hypertensive surge is followed by sustained hypotension; reserpine therefore has a paradoxical early hypertensive effect before its antihypertensive action becomes established over 24–48 hours
• C) VMAT2 blockade selectively depletes dopamine from central dopaminergic neurons without affecting peripheral sympathetic NE stores, because peripheral sympathetic terminals express VMAT1 rather than VMAT2 — reserpine is therefore an antipsychotic rather than an antihypertensive, producing its therapeutic effect by depleting mesolimbic dopamine while leaving peripheral vascular sympathetic tone intact
• D) VMAT2 blockade prevents vesicular NE release during action potentials but does not deplete total NE stores — the unpackaged NE remains safely in the cytoplasm and can be re-packaged when VMAT2 blockade is reversed; reserpine therefore produces a short-acting, fully reversible sympatholytic effect that terminates within hours of drug discontinuation when VMAT2 function is restored
• E) VMAT2 blockade reduces NE synthesis by eliminating product feedback inhibition — when NE cannot be packaged into vesicles, cytoplasmic NE concentration rises and inhibits tyrosine hydroxylase through end-product inhibition, reducing further NE production; the depletion of NE stores therefore occurs primarily through reduced synthesis rather than through increased degradation or impaired vesicular packaging

9. Monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) are the two principal enzymes that degrade catecholamines. Which of the following correctly describes the location and primary role of each enzyme in the inactivation of norepinephrine?

• A) MAO and COMT are both exclusively hepatic enzymes responsible for first-pass metabolism of orally administered catecholamines — they play no role in terminating the action of NE released at sympathetic neuroeffector junctions, where termination is entirely dependent on NET reuptake; this is why parenteral but not oral epinephrine is effective as a sympathomimetic agent
• B) MAO is located exclusively in the synaptic cleft where it rapidly degrades NE within milliseconds of release — MAO is the primary termination mechanism for NE action at the neuroeffector junction, with COMT serving as a secondary backup enzyme that degrades any NE that escapes MAO and enters the circulation; this is why MAO inhibitors produce such immediate and potent sympathomimetic effects
• C) COMT is the primary NE inactivation enzyme at sympathetic neuroeffector junctions, located on the presynaptic terminal membrane where it methylates NE immediately after release — NET reuptake serves only as a recycling mechanism for COMT metabolites; MAO is present only in the GI tract where it prevents dietary tyramine from reaching the systemic circulation
• D) MAO and COMT are both exclusively intravesicular enzymes — they protect vesicular NE stores from degradation by maintaining a low intravesicular pH that inhibits any contaminating proteases; when vesicles are disrupted by reserpine, the released MAO and COMT degrade the displaced NE before it can reach the synaptic cleft
• E) MAO is located on the outer mitochondrial membrane inside neurons and some non-neuronal cells — it deaminates catecholamines (including NE, dopamine, and serotonin) that are in the cytoplasm; it is the primary enzyme for degrading NE that has leaked from vesicles or been taken up by NET from the cleft; COMT is located in the cytoplasm of postsynaptic cells and non-neuronal tissues (liver, kidney, gut) — it methylates the catechol ring of NE that has diffused away from the synapse or entered the circulation; together they produce the principal urinary NE metabolite vanillylmandelic acid (VMA); elevated urinary VMA and metanephrines confirm the diagnosis of pheochromocytoma

10. A patient presents to the emergency department after eating aged cheese and Chianti wine while taking phenelzine (an irreversible MAO inhibitor prescribed for depression). Her blood pressure is 220/140 mmHg and she has a severe headache. Which of the following most accurately explains the pharmacodynamic mechanism of this hypertensive crisis?

• A) The tyramine in aged cheese and wine is directly absorbed into the systemic circulation and activates alpha-1 adrenergic receptors on vascular smooth muscle — MAO inhibition is not part of the mechanism; the cheese-wine combination produces hypertension through direct tyramine adrenergic agonism that occurs even in patients not taking MAO inhibitors, explaining why these foods carry dietary warnings for all patients regardless of medication
• B) Tyramine in aged cheese and wine is normally inactivated by MAO-A in the gut wall and liver during first-pass metabolism, preventing it from reaching the systemic circulation in significant quantities — phenelzine irreversibly inhibits both MAO-A and MAO-B throughout the body including the gut and liver; with gut and hepatic MAO inhibited, dietary tyramine bypasses first-pass metabolism and reaches the systemic circulation intact; tyramine is taken up into sympathetic terminals via NET and displaces vesicular NE by the indirect sympathomimetic mechanism; intraneuronal MAO that would normally degrade displaced NE is also inhibited, allowing massive NE accumulation and release — producing the hypertensive crisis
• C) Phenelzine inhibits NET in addition to MAO, preventing tyramine uptake into sympathetic terminals — tyramine therefore accumulates in the systemic circulation and activates beta-1 adrenergic receptors directly, producing tachycardia and increased cardiac output; the hypertension is a beta-1-mediated effect rather than an alpha-1-mediated vasoconstrictive response
• D) The hypertensive crisis reflects a pharmacokinetic interaction — phenelzine inhibits CYP2D6 (the enzyme responsible for tyramine metabolism in the liver), allowing tyramine to accumulate in plasma; tyramine then acts as a direct vasoconstrictor at alpha-1 receptors; the hypertensive response is proportional to plasma tyramine concentration, which rises predictably with the tyramine content of the food
• E) The aged cheese and wine contain tyramine that competes with phenelzine for MAO binding — tyramine displaces phenelzine from MAO, transiently restoring MAO activity; the sudden restoration of MAO activity causes rapid degradation of accumulated intraneuronal NE, releasing toxic oxidative metabolites that damage vascular endothelium and produce inflammatory hypertension

11. Botulinum toxin is used therapeutically for conditions including hyperhidrosis (excessive sweating), cervical dystonia, and spasticity. Which step in neurotransmitter release does it block, and which synapses are affected?

• A) Botulinum toxin blocks the vesicular acetylcholine transporter (VAChT), preventing ACh packaging into synaptic vesicles — without vesicular ACh, quantal release cannot occur; the toxin is specific for peripheral cholinergic terminals because VAChT in the CNS has a different splice variant that is insensitive to botulinum toxin; recovery requires resynthesis of VAChT protein over 2–3 days
• B) Botulinum toxin blocks the voltage-gated calcium channels on cholinergic nerve terminals by a direct pore-blocking mechanism, preventing calcium influx and therefore ACh exocytosis — it is selectively toxic to cholinergic neurons because only cholinergic terminals express the N-type calcium channels that botulinum toxin blocks; recovery occurs rapidly when the toxin dissociates from the calcium channel within hours to days
• C) Botulinum toxin inhibits choline acetyltransferase (ChAT) irreversibly, preventing ACh synthesis — without ACh synthesis, existing vesicular stores are depleted within minutes of administration and ACh release ceases; because ChAT is also expressed in adrenergic neurons (where it synthesizes the ACh used for ganglionic transmission), botulinum toxin also blocks norepinephrine release from sympathetic terminals by depleting ganglionic ACh
• D) Botulinum toxin blocks the high-affinity choline transporter (CHT1), preventing choline reuptake and thereby starving ACh synthesis — the depletion of choline leads to progressive ACh store depletion over days to weeks; botulinum toxin is selective for cholinergic neurons because only cholinergic terminals express CHT1; therapeutic effects wear off as choline is obtained from alternative sources including phosphatidylcholine hydrolysis
• E) Botulinum toxin is taken up into cholinergic nerve terminals by receptor-mediated endocytosis and cleaves specific SNARE proteins (synaptobrevin, syntaxin, or SNAP-25 depending on the serotype) that are required for synaptic vesicle fusion with the plasma membrane — without functional SNARE complexes, calcium-triggered exocytosis cannot occur and ACh release is blocked; affected synapses include neuromuscular junctions (producing muscle paralysis — therapeutic for dystonia and spasticity), autonomic ganglia (producing ganglionic blockade), and sympathetic cholinergic sudomotor terminals (producing anhidrosis — therapeutic for hyperhidrosis); recovery requires sprouting of new nerve terminals over weeks to months

12. Which of the following correctly describes the difference between presynaptic autoreceptors and presynaptic heteroreceptors at autonomic nerve terminals, and gives a clinical example of each?

• A) Presynaptic autoreceptors detect the nerve terminal's own released neurotransmitter and provide feedback regulation of further release — alpha-2 adrenergic autoreceptors on sympathetic terminals detect released NE and inhibit further NE release through Gi-coupled adenylyl cyclase inhibition and reduced calcium entry, providing a self-limiting brake on sympathetic neurotransmission; clonidine activates presynaptic alpha-2 autoreceptors peripherally (in addition to its central action) to reduce NE release — heteroreceptors on the same terminal respond to transmitters released from adjacent neurons or from other sources, modulating release of the primary transmitter; prostaglandin E2 receptors and adenosine receptors on sympathetic terminals are heteroreceptors that inhibit NE release, contributing to the anti-sympathetic effects of NSAIDs (which increase NE release by removing prostaglandin E2 inhibition) and explaining part of methylxanthine (caffeine) sympathomimetic activity through adenosine receptor antagonism
• B) Presynaptic autoreceptors are located exclusively on the postsynaptic cell and respond to the primary neurotransmitter released from the presynaptic terminal — they provide negative feedback to the presynaptic terminal through a retrograde signaling mechanism; presynaptic heteroreceptors are located on the presynaptic terminal and respond to transmitters from adjacent neurons
• C) Presynaptic autoreceptors only exist at dopaminergic synapses in the CNS — peripheral autonomic nerve terminals lack autoreceptors because the synaptic cleft is too wide for released NE to diffuse back to the presynaptic terminal in sufficient concentrations; heteroreceptors exist at both central and peripheral synapses and are responsible for all modulatory control of autonomic neurotransmitter release
• D) Presynaptic autoreceptors and heteroreceptors are functionally identical — both are GPCR receptors on the presynaptic terminal that inhibit neurotransmitter release through Gi coupling; the distinction between auto and hetero refers only to which transmitter ligand activates them, not to any difference in signaling mechanism or clinical significance
• E) Presynaptic autoreceptors are located on the postsynaptic cell body and detect excess neurotransmitter levels as a safety mechanism — when activated, they send a retrograde signal instructing the presynaptic terminal to reduce synthesis rather than reduce release, conserving energy by reducing ChAT or TH activity; heteroreceptors are autoreceptors that have been desensitized by chronic transmitter exposure

13. A patient with myasthenia gravis (a disease in which autoantibodies destroy nicotinic NM receptors at the neuromuscular junction, reducing the number of functional receptors available for ACh binding) is treated with pyridostigmine, a reversible AChE inhibitor that does not cross the blood-brain barrier. Which of the following correctly explains why pyridostigmine improves neuromuscular transmission in this disease despite not increasing NM receptor number?

• A) By inhibiting AChE in the synaptic cleft at the neuromuscular junction, pyridostigmine prevents ACh hydrolysis and allows released ACh to remain in the cleft longer and at higher concentrations — the prolonged higher ACh concentration increases the probability that ACh molecules will find and bind the reduced number of remaining functional NM receptors, partially compensating for the receptor loss and improving neuromuscular transmission; because pyridostigmine does not cross the blood-brain barrier, central cholinergic effects are avoided, and because it is reversible, its action terminates predictably without permanent AChE inhibition
• B) Pyridostigmine directly activates nicotinic NM receptors as a partial agonist at the neuromuscular junction, bypassing the need for ACh to bind the reduced receptor pool — the partial agonist activity is sufficient to generate end-plate potentials in most muscle fibers despite the autoantibody-mediated receptor loss; pyridostigmine is classified as an AChE inhibitor because this classification reflects its quaternary ammonium structure rather than its actual mechanism of action
• C) Pyridostigmine increases ACh synthesis in motor nerve terminals by activating ChAT through an allosteric mechanism — more ACh is synthesized per action potential, providing a larger quantal release that saturates even the reduced NM receptor pool; the increased quantal size compensates for the reduced receptor density and restores normal end-plate potential amplitude
• D) Pyridostigmine blocks the autoantibody binding site on the NM receptor, competitively displacing the pathological IgG antibodies and restoring functional receptor availability — the AChE inhibitory activity of pyridostigmine is an off-target effect unrelated to its therapeutic mechanism in myasthenia gravis; the primary therapeutic action is autoantibody displacement
• E) Pyridostigmine activates presynaptic alpha-2 autoreceptors at the neuromuscular junction, removing tonic inhibition of ACh release — more ACh is released per action potential, increasing the quantal content of end-plate potentials; the increased ACh release compensates for the reduced NM receptor density by ensuring that even with fewer functional receptors, enough remain activated to reach the threshold for muscle action potential generation

14. Two drugs both increase norepinephrine availability at adrenergic receptors but through completely different mechanisms: cocaine blocks the norepinephrine transporter (NET) and tyramine releases NE via the indirect sympathomimetic mechanism. Which of the following correctly predicts a key difference in their clinical effects that follows directly from the mechanistic difference?

• A) Cocaine and tyramine both produce identical clinical sympathomimetic profiles because they both ultimately increase NE at adrenergic receptors — the mechanistic difference between NET blockade and indirect NE release is pharmacologically irrelevant to the end-organ response, since adrenergic receptors cannot distinguish between NE that has accumulated due to reuptake inhibition and NE that has been released by displacement
• B) Cocaine produces tachyphylaxis after repeated dosing but tyramine does not — cocaine depletes NET protein from the presynaptic terminal through a receptor downregulation mechanism, reducing its own ability to block NE reuptake; tyramine avoids tachyphylaxis because its mechanism does not involve NET and therefore does not trigger NET downregulation
• C) Tyramine produces tachyphylaxis with repeated dosing because it depletes vesicular NE stores faster than they can be resynthesized — each dose of tyramine releases a portion of stored NE; with repeated dosing, vesicular stores diminish and subsequent doses produce progressively smaller NE releases and smaller sympathomimetic responses; cocaine does not produce this type of tachyphylaxis because its mechanism (NET blockade) does not deplete NE stores — it simply prolongs the action of NE that is released by normal action potential-driven exocytosis
• D) Cocaine and tyramine both cause tachyphylaxis through depletion of alpha-2 autoreceptors — repeated NE surges from either mechanism downregulate presynaptic alpha-2 autoreceptors, removing the inhibitory brake on NE release and paradoxically increasing NE release with each successive dose; the net effect is escalating sympathomimetic responses rather than diminishing ones
• E) Cocaine requires intact action potential-driven NE release to produce its sympathomimetic effects, while tyramine does not — this means that cocaine is ineffective as a sympathomimetic when ganglionic blockers are administered simultaneously, while tyramine continues to release NE from postganglionic terminals even in the presence of ganglionic blockade because its mechanism bypasses neural firing entirely

15. Having worked through the complete life cycle of acetylcholine and norepinephrine in this module, which of the following statements most accurately captures why understanding the steps of neurotransmitter synthesis, storage, release, and inactivation is essential for predicting the effects of autonomic drugs?

• A) Understanding neurotransmitter life cycle steps is important mainly for basic scientists — clinicians only need to know the receptor-level effects of drugs; the molecular steps of synthesis, storage, release, and inactivation are not relevant to clinical drug selection or the prediction of side effects in patients
• B) Every autonomic drug acts by intervening at one specific step in the neurotransmitter life cycle — by identifying which step is targeted, a clinician can immediately predict: whether the drug increases or decreases neurotransmitter availability, which synapses are affected (based on whether that step is shared between divisions or division-specific), whether the drug will produce tachyphylaxis (if it depletes a finite store), whether its effect will be prolonged (if it involves irreversible enzyme inhibition or receptor turnover), and what the full pattern of organ effects will be; this mechanistic framework converts a list of drug names into a logical network of predictable consequences
• C) Understanding neurotransmitter synthesis steps is important mainly for explaining drug toxicity — therapeutic effects of autonomic drugs are always mediated at the receptor level; synthesis, storage, and release steps are only relevant when understanding why a drug produces adverse effects rather than therapeutic ones
• D) The neurotransmitter life cycle is relevant only for drugs acting at peripheral synapses — centrally acting autonomic drugs such as clonidine and methyldopa bypass the peripheral neurotransmitter cycle entirely and act through receptor mechanisms that are independent of the synthesis, storage, release, and reuptake steps covered in this module
• E) Understanding individual steps in the neurotransmitter life cycle is less important than memorizing the complete pharmacological profile of each specific drug — drug effects are too complex and too dependent on individual patient factors to be predictable from mechanistic principles alone; a comprehensive drug reference is a more reliable guide to clinical practice than a mechanistic framework